Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343040 | 0.98 | SLC18A3 (0.59) | SLC18A3ALDH1A1KDM4EPOLBCA1 | |
| SCHEMBL491782 | 0.96 | SLC18A3 (0.57) | SLC18A3ALDH1A1KDM4EPOLBCA1 | |
| SCHEMBL30456355 | 0.96 | SLC18A3 (0.57) | SLC18A3ALDH1A1KDM4EPOLBCA1 | |
| SCHEMBL30456604 | 0.96 | SLC18A3 (0.57) | SLC18A3ALDH1A1KDM4EPOLBCA1 | |
| SCHEMBL11245821 | 0.96 | SLC18A3 (0.57) | SLC18A3ALDH1A1KDM4EPOLBCA1 | |
| SCHEMBL23595723 | 0.96 | SLC18A3 (0.57) | SLC18A3ALDH1A1KDM4EPOLBCA1 | |
| SCHEMBL13917788 | 0.96 | SLC18A3 (0.57) | SLC18A3ALDH1A1KDM4EPOLBCA1 | |
| SCHEMBL10562193 | 0.96 | SLC18A3 (0.57) | SLC18A3ALDH1A1KDM4EPOLBCA1 | |
| SCHEMBL31122399 | 0.96 | SLC18A3 (0.57) | SLC18A3ALDH1A1KDM4EPOLBCA1 | |
| SCHEMBL28448071 | 0.96 | SLC18A3 (0.57) | SLC18A3ALDH1A1KDM4EPOLBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2012500807-A | — | — | 2012-01-12 | — | — | JP | claimed |
| US-20110160238-A1 | OCTAHYDROQUINOLIZINES FOR ANTIDIABETIC TREATMENT | 55PHARMA DRUG DISCOVERY & DEVELOPMENT AG (AT) | 2011-06-30 | — | — | US | claimed |
| EP-2315766-A1 | OCTAHYDROQUINOLIZINES FOR ANTIDIABETIC TREATMENT | 55pharma Drug Discovery & Development AG (AT) | 2011-05-04 | — | — | EP | claimed |
| WO-2010022412-A1 | OCTAHYDROQUINOLIZINES FOR ANTIDIABETIC TREATMENT | 55PHARMA DRUG DISCOVERY & DEVELOPMENT AG (AT) | 2010-03-04 | — | — | WO | claimed |
| CN-113874015-B | Thienopyridine inhibitors of RIPK2 | 细胞基因公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-3897630-B1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORP (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023009585-A2 | TRANSTHYRETIN STABILIZING COMPOUNDS | PROTEGO BIOPHARMA, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| CN-113874015-A | Thienopyridine inhibitors of RIPK2 | 细胞基因公司 | 2021-12-31 | — | — | CN | disclosed |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| EP-3897630-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020132384-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-4684731-A | NEUROLEPTIC, ANTIEMETIC, ANALGESIC | HOFFMANN-LA ROCHE INC. (US) | 1987-08-04 | — | — | US | disclosed |
| US-4391978-A | NEUROLEPTIC AGENTS, ANTIEMETICS, ANALGESICS | HOFFMANN-LA ROCHE INC. (US) | 1983-07-05 | — | — | US | disclosed |
| US-4338444-A | ANTIPSYCHOTICS, ANTIEMETICS AND ANALGESICS | HOFFMANN-LA ROCHE INC. (US) | 1982-07-06 | — | — | US | disclosed |
| US-4329467-A | USED AS ANTIPSYCHOTICS, ANTIEMETICS, AND ANALGESICS | HOFFMANN-LA ROCHE INC. (US) | 1982-05-11 | — | — | US | disclosed |
| US-4316030-A | Phenyl-quinolizidines | HOFFMANN-LA ROCHE INC. (US) | 1982-02-16 | — | — | US | disclosed |
| US-4306067-A | ANTIPSYCHOTICS, ANTIEMETICS, AND ANALGESICS | HOFFMANN-LA ROCHE INC. (US) | 1981-12-15 | — | — | US | disclosed |
| US-4272627-A | ANALGESICS, ANTIEMETICS, ANTIPSYCHOTICS | HOFFMANN-LA ROCHE INC. (US) | 1981-06-09 | — | — | US | disclosed |
| US-4236010-A | ANTIPYCHOTIC, ANTIEMENTIC, ANALGESIC | HOFFMANN-LA ROCHE INC. (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160238-A1 | OCTAHYDROQUINOLIZINES FOR ANTIDIABETIC TREATMENT | SLC5A2, GPR119, ZYX | SLC18A3 1349/4885ALDH1A1 4225/4885KDM4E 780/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | SLC18A3 4147/4885ALDH1A1 4498/4885KDM4E 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.